SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Vitamin B12 | Erythropoietin / EPO | L-Carnitine / Levocarnitine |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Essential cobalamin nutrient; several prescription forms exist | Erythropoiesis-stimulating hormone / medicine family | Endogenous nutrient and prescription active ingredient in product-specific contexts |
| PrimeCore Class | Class AApproved in a bounded context | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Vitamin B12 is classified here as Essential cobalamin nutrient; several prescription forms exist. Clinical benefit is established for correcting specific deficiency states, not as a universal energy, weight-loss or performance intervention. Food, supplement and prescription-drug frameworks differ by product and jurisdiction; the catalogue name does not identify cyanocobalamin, hydroxocobalamin or methylcobalamin. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | EPO is an erythropoietic hormone and an ambiguous catalogue label, not a verified product identity. Authorised epoetin medicines treat selected anaemias, with risks including hypertension and thrombosis. Specific ESA warnings include stroke, cardiovascular events and tumour progression in defined settings. No endurance-enhancement recommendation is made. | L-Carnitine / Levocarnitine is classified here as Endogenous nutrient and prescription active ingredient in product-specific contexts. Authorised levocarnitine products exist for defined deficiency-related contexts, while wellness and body-composition claims require separate evidence. U.S. prescription labels exist for defined levocarnitine products; that status does not authenticate a catalogue vial or any Lipo-C blend. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions